If you have tried medication after medication and still do not feel like yourself, you are not out of options. Here is what treatment resistant depression is, why it happens, and what advanced care can offer.

Depression is one of the most common health conditions in the world, and it is also one of the most misunderstood. Many people believe that if a first antidepressant does not work, a second one surely will, or that enough time in therapy will eventually turn things around. For a large number of people, this is simply not how it goes. Research shows that between one third and two thirds of people with major depression do not get better on their first prescribed medication, and roughly 15 to 33 percent do not respond even after trying several different treatments. When depression persists despite genuine, well managed attempts at standard care, it has a name: treatment resistant depression.

If this sounds familiar, please know that this is a recognized medical condition, not a personal failing, and not a sign that nothing will ever help. It simply means that your depression needs a different kind of approach, one that goes beyond the standard first and second line options most people are offered.

What Treatment Resistant Depression Actually Means

Clinically, depression is generally considered treatment resistant when at least two adequate trials of antidepressants, from two different drug classes, have failed to produce meaningful improvement. An adequate trial means the right dose, taken consistently, for a long enough period, usually at least eight weeks. This distinction matters because sometimes what looks like treatment resistance is actually a dose that was too low, a trial that was stopped too early, or a medication that was not being taken consistently due to side effects. A proper evaluation should always rule these possibilities out first.

Once true treatment resistance is confirmed, the numbers can be sobering. In the landmark STAR*D trial, one of the largest studies ever conducted on real world depression treatment, only 37 percent of patients reached remission on their first medication. After a second treatment step, the cumulative remission rate rose to about 51 percent, and by the fourth treatment step, it reached only 67 percent, meaning roughly one in three people still had not found relief after four separate rounds of trial and error. Fewer than half of all patients achieved lasting, sustained remission even after exhausting these options.

Why Standard Treatment Stops Working for Some People

There is no single reason depression becomes resistant to standard treatment. For some people, an underlying medical condition such as thyroid dysfunction, chronic pain, or sleep apnea is quietly working against recovery. For others, a co-occurring condition such as anxiety, PTSD, or substance use complicates the picture. Life circumstances, genetics that affect how the body metabolizes medication, and the simple biological reality that depression itself changes brain function over time can all play a role. This is why it is important that a review of these conditions is part of any standard psychiatric assessment. At TMS Life, for all clients starting treatment at the clinic we review and make recommendations around bloodwork, sleep study assessments and chronic pain management referrals. 

This is also where operational stress injuries deserve special mention. For military members, veterans, and RCMP personnel, depression is frequently intertwined with trauma exposure, chronic stress, and physical injury in ways that standard primary care treatment was never designed to address. This population often requires a more specialized, trauma informed approach from the very beginning.

The Limits of Simply Switching Medications

One of the more sobering findings from decades of depression research is this: no single medication switching strategy has proven reliably better than another. Moving from one antidepressant to a different one, or adding a second medication to boost the effect of the first, can help some people, but the STAR*D trial and others like it found that these strategies produced roughly similar, and often modest, results across the board. Meanwhile, patients who need more treatment steps tend to have higher rates of relapse down the road.

This does not mean medication and therapy are not valuable. They remain the right starting point for most people, and many people do get well with them. But when someone has genuinely given these standard approaches a fair chance and is still struggling, continuing to cycle through the same category of options, another pill, another few months of waiting to see if it helps, is often not the most effective use of time, especially when someone is suffering in the meantime.

Where Advanced Treatment Options Come In

This is the point where advanced, evidence based neuromodulation and interventional treatments become genuinely important to understand. Options such as repetitive transcranial magnetic stimulation, known as TMS, and ketamine assisted therapy work through mechanisms that are fundamentally different from oral medication. Rather than relying on the slow, systemic effects of a daily pill, these treatments act more directly and often more quickly on the brain circuits involved in depression.

TMS uses focused magnetic pulses, delivered in an outpatient setting without anesthesia, to stimulate specific brain regions involved in mood regulation. It carries a favorable safety profile and does not come with the systemic side effects associated with many medications. Ketamine assisted therapy, delivered under medical supervision, has shown the ability to produce meaningful improvement in mood, sometimes within days rather than the weeks or months typically required for antidepressants to take effect. For many patients who have not responded to conventional care, these approaches offer a genuinely different path forward rather than simply more of the same.

The challenge many people face is access. These advanced options are not yet widely available through the public system, and where they are offered, wait times can be long and eligibility criteria narrow. This gap leaves many people with treatment resistant depression stuck, aware that other options exist but unable to reach them in a timely way.

Why a Specialized Assessment Matters

At TMS Life Clinic, our assessments are designed specifically for people in this situation, those for whom standard medication and therapy have not delivered the relief they deserve. Rather than offering a single treatment to everyone, we take the time to understand your full history, including previous medication trials, any co-occurring conditions, and, for our veteran and RCMP clients, the operational stress injuries that so often accompany depression in these populations.

From there, we build an individualized treatment pathway. For many patients, this means TMS since it has the best evidence based and is best tolerated for treatment-resistant depression. For others, it means ketamine treatments or referral for more intensive treatments such as ECT through outpatient or inpatient programs. Our goal is not to replace the care you have already received, but to open the door to advanced options that are either not currently available in the public system or difficult to access, and to do so with the kind of thorough, personalized planning that treatment resistant depression genuinely requires.

If medication and therapy have not been enough, that does not mean you have run out of options. It may simply mean it is time for a re-assessment and consideration of advanced treatments that are evidence based but difficult to access within the Canadian Public Healthcare System.

Reference

Little, A. (2009). Treatment-resistant depression. American Family Physician, 80(2), 167-172.